As of 2025-12-19, the Intrinsic Value of Haemonetics Corp (HAE) is 78.11 USD. This HAE valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 79.98 USD, the upside of Haemonetics Corp is -2.30%.
The range of the Intrinsic Value is 49.57 - 155.08 USD
Based on its market price of 79.98 USD and our intrinsic valuation, Haemonetics Corp (HAE) is overvalued by 2.30%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 49.57 - 155.08 | 78.11 | -2.3% |
| DCF (Growth 10y) | 65.97 - 184.84 | 98.33 | 22.9% |
| DCF (EBITDA 5y) | 77.97 - 89.42 | 84.81 | 6.0% |
| DCF (EBITDA 10y) | 92.76 - 113.74 | 104.02 | 30.1% |
| Fair Value | 89.83 - 89.83 | 89.83 | 12.31% |
| P/E | 79.95 - 126.47 | 101.77 | 27.2% |
| EV/EBITDA | 46.45 - 91.11 | 76.77 | -4.0% |
| EPV | 38.37 - 54.99 | 46.68 | -41.6% |
| DDM - Stable | 34.01 - 102.20 | 68.10 | -14.8% |
| DDM - Multi | 49.18 - 115.47 | 69.05 | -13.7% |
| Market Cap (mil) | 3,743.86 |
| Beta | 0.12 |
| Outstanding shares (mil) | 46.81 |
| Enterprise Value (mil) | 4,672.17 |
| Market risk premium | 4.60% |
| Cost of Equity | 8.28% |
| Cost of Debt | 4.25% |
| WACC | 7.11% |